{
  "docId": "019de076-3deb-7779-9c43-c38f834a1cfd",
  "docSlug": "60ad9a5894e93b6af8b1b5bddd2d87e3",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 30,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "go_to_market",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes a clinical case study image showing patient response to therapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3deb-7779-9c43-c38f834a1cfd/10",
  "deckHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd",
  "deckJsonHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd.json",
  "deckAnchorHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.46,
        "x": 0.02,
        "y": 0.25
      },
      "kind": "image",
      "text": "Clinical imaging showing progression from 177Lu to 225Ac therapy",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc0fc47f-1296-43ef-aa4e-ea28ca83de9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.48,
        "y": 0.5
      },
      "kind": "list",
      "text": "In ~Q1 2024 Fusion will be able to report: Data for 20-30 patients, including safety and efficacy results (incl. PSA50 responses, ORR, rPFS). In 2024: Anticipated completion of Phase 2 study. Initiation of Phase 3 study activities.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74d74a8e-d9e6-4ec7-be0a-4fd9f08f2362",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.5,
        "x": 0.48,
        "y": 0.25
      },
      "kind": "list",
      "text": "Initial Approval: Patients who progressed on or after 177Lu-PSMA - area of highest unmet need and a rapidly growing market. Follow-On Opportunities: Potential to expand into the treatment of 177Lu-naive patients and move to early lines of therapy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1b4855a-03aa-459e-8381-0775b04fe479",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Kratochwil et al. (2016) J. Nucl. Med. 57:1941-1944",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64bc2778-e198-499e-8496-2b550a780290",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.295,
        "x": 0.035,
        "y": 0.035
      },
      "kind": "title",
      "text": "Development Strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "281569af-a68d-492c-8300-3dcbd6597bd9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 10,
      "beatId": "112b9300-e62a-468e-ab16-1feeb3a2395e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Opportunity",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The document discusses the market opportunity for radiopharmaceuticals and the potential for Fusion Pharmaceuticals' therapies",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}